Algert Global’s CytomX Therapeutics CTMX Stock Holding History

Algert Global’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$341K	Buy	+90,900	New	+$347K	﹤0.01%	1122
2025 Q1	–	Sell	-33,570	Closed	-$34.6K	–	1205
2024 Q4	$34.6K	Buy	+33,570	New	+$36.1K	﹤0.01%	1147
2022 Q3	–	Sell	-30,340	Closed	-$56K	–	1200
2022 Q2	$56K	Buy	+30,340	New	+$58.1K	﹤0.01%	1147
2020 Q1	–	Sell	-32,403	Closed	-$269K	–	428
2019 Q4	$269K	Buy	32,403 +11,560	+55%	+$78K	0.08%	276
2019 Q3	$154K	Sell	20,843 -28,280	-58%	-$279K	0.06%	298
2019 Q2	$551K	Buy	+49,123	New	+$515K	0.2%	159
2019 Q1	–	Sell	-75,586	Closed	-$1.14M	–	332
2018 Q4	$1.14M	Buy	75,586 +8,777	+13%	+$130K	0.32%	111
2018 Q3	$1.24M	Buy	66,809 +45,159	+209%	+$1.03M	0.27%	141
2018 Q2	$495K	Buy	21,650 +350	+2%	+$8.94K	0.1%	244
2018 Q1	$606K	Sell	21,300 -29,933	-58%	-$854K	0.12%	233
2017 Q4	$1.08M	Buy	51,233 +5,380	+12%	+$112K	0.26%	158
2017 Q3	$833K	Buy	45,853 +11,050	+32%	+$172K	0.19%	183
2017 Q2	$539K	Buy	+34,803	New	+$525K	0.15%	213

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Algert Global's CTMX Position: Q2 2026 in Review

Algert Global opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 90,900 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #1122 among its holdings. This is a return to the name: Algert Global previously reported a position in CTMX as recently as Q4 2024.

Algert Global first reported a position in CTMX in Q2 2017 and has held it in 13 quarters since. The position peaked at $1.24M in Q3 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Algert Global held 90,900 shares of CytomX Therapeutics worth $341K as of Q2 2026.
CytomX Therapeutics was a new Algert Global position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1122 holding.
Algert Global first reported a position in CytomX Therapeutics in Q2 2017 and has held it in 13 quarters since.
Algert Global's CytomX Therapeutics position peaked at $1.24M in Q3 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.